Business context and reporting period
Entity mismatch: The request metadata names Kyntra Bio, Inc., but the supplied Form 10-K is for FibroGen, Inc. (Nasdaq: FGEN). This summary covers FibroGen’s fiscal year ended December 31, 2019; the filing was signed March 2, 2020. It is an annual report, not a standalone fourth-quarter filing.
FibroGen is a biopharmaceutical company developing therapies for anemia, fibrosis and cancer. Roxadustat had approvals in China for CKD anemia in dialysis and non-dialysis patients and in Japan for dialysis patients; its U.S. NDA was accepted for review in February 2020. Pamrevlumab was in Phase 3 development for idiopathic pulmonary fibrosis and pancreatic cancer and Phase 2 for Duchenne muscular dystrophy.
Financial performance and liquidity
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Revenue | $256.6 million | $213.0 million |
| Operating expenses | $345.9 million | $299.7 million |
| Loss from operations | $89.3 million | $86.7 million |
| Net loss | $77.0 million | $86.4 million |
| Net loss per share, diluted | $0.89 | $1.03 |
| Net cash used in operating activities | $78.7 million | $76.1 million |
Revenue increased 20%, but included collaboration milestones and a significant prior-year product-revenue adjustment. The operating loss equaled about 35% of revenue and net loss about 30%; conventional product margins are not informative given the collaboration-heavy revenue mix and limited commercial sales. China roxadustat drug-product revenue was $1.7 million net; total reported product revenue was negative $34.6 million after a $36.3 million reduction to the 2018 Japan API sale estimate.
At year-end, cash and cash equivalents were $126.3 million, short-term investments $407.5 million, long-term investments $61.1 million, and working capital $599.7 million. Cash, investments and accounts receivable totaled $623.3 million, down $117.6 million from year-end 2018. Total assets were $857.4 million; stockholders’ equity was $516.1 million. The filing does not report conventional funded debt; it reports $51.9 million of lease liabilities and $16.8 million of product-development obligations, principally TEKES loans. No cash dividend was planned.
Quarterly results were uneven: Q4 2019 revenue was $8.0 million and net loss $98.1 million, compared with Q4 2018 revenue of $108.1 million and net income of $21.0 million. Q2 2019 included $191.6 million of revenue and $116.0 million of net income, reflecting milestone recognition. Quarterly revenue and earnings are therefore not a smooth indicator of underlying operating trends.
Material changes versus the prior period
- Total revenue rose $43.6 million year over year, largely as license revenue increased to $177.1 million from $22.3 million, including $130.0 million in Astellas milestones tied to the planned European MAA and a $50.0 million AstraZeneca U.S. NDA milestone.
- Development and other revenue declined 9% to $114.1 million, mainly because roxadustat Phase 3 co-development activity was substantially completed.
- R&D expense fell 11% to $209.3 million, while selling, general and administrative expense more than doubled to $135.5 million, reflecting China launch preparation, co-promotion costs and other increases.
- Net loss narrowed by $9.5 million, aided by higher interest and other income; operating loss nevertheless widened by $2.6 million.
- FY 2019 revenue included a $36.3 million downward revision to the 2018 Japan API sale estimate after Japan’s listed price and manufacturing yield became known. The year-end balance sheet also included $180.0 million of unbilled regulatory milestones, netted against related deferred revenue to a $125.2 million contract asset.
Outlook, management commentary, risks and unusual items
- Management expected continued annual losses and higher spending over the coming years, including increased pamrevlumab Phase 3 costs. It stated existing cash, investments, accounts receivable and expected collaboration revenue should fund operations for at least 12 months from the filing date; this is not a longer-term funding assurance.
- The FDA set a December 20, 2020 PDUFA goal date for the roxadustat NDA. Astellas planned to submit the European MAA in Q2 2020. Regulatory approval, safety review, labeling, pricing and reimbursement remained uncertain.
- China commercialization depends on reimbursement, hospital listings, distribution and pricing. The NRDL negotiated price for a 50 mg capsule was RMB 95 for the list period beginning January 2020, with renegotiation expected after 2021. Management described hospital listing as a significant market-access constraint.
- COVID-19 disruptions were an emerging risk at filing: FibroGen cited potential impacts on China operations, supply, hospital listings, sales and clinical-trial enrollment, with the scale and duration then uncertain.
- Other key risks include reliance on AstraZeneca and Astellas, third-party manufacturing and clinical contractors, competition from ESAs and other HIF-PH inhibitors, patent challenges, and the safety profile and regulatory outcome of product candidates. Roxadustat’s Japan label includes a serious thromboembolism warning.
- Founder and CEO Thomas Neff died in August 2019; Enrique Conterno was appointed CEO in January 2020. The auditor gave an unqualified opinion on the financial statements and concluded internal control over financial reporting was effective. Revenue recognition for regulatory milestones was identified as a critical audit matter because management’s probability assessments involved significant judgment.
Most important facts for investors to verify
- Confirm the issuer identity: the supplied filing is FibroGen, not Kyntra Bio.
- Track FDA review and the December 20, 2020 goal date, European filing progress, and any safety, labeling or benefit-risk decisions for roxadustat.
- Assess China launch traction through product sales, hospital listings, reimbursement, price adjustments and the 50/50 collaboration economics.
- Reconcile milestone-driven revenue and the $36.3 million Japan API adjustment; monitor collection of the $180.0 million unbilled milestones and resulting contract assets.
- Monitor cash burn, investment balances and collaboration funding against management’s stated 12-month runway, including the $53.1 million accrued China co-promotion amount.
- Review COVID-19 effects on manufacturing, supply, trials and commercialization, plus clinical and regulatory progress for pamrevlumab.